Back to top
more

CRISPR Therapeutics (CRSP)

(Real Time Quote from BATS)

$55.24 USD

55.24
474,001

-0.49 (-0.88%)

Updated May 24, 2024 03:48 PM ET

After-Market: $55.25 +0.01 (0.02%) 4:06 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 249)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Benjamin Rains headshot

3 Strong Pharmaceutical and Biotech Stocks to Buy for Coronavirus Immunity

Let's dive into three large-cap pharmaceutical and biotech stocks that appear set to grow during the pandemic-induced downturn and the eventual recovery...

Why Is CRISPR Therapeutics AG (CRSP) Up 22.9% Since Last Earnings Report?

CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Kevin Cook headshot

Bull of the Day: Vertex Pharma (VRTX)

While COVID-19 interrupts clinical trials, the champ of cystic fibrosis is about to repeat another year of 37% revenue growth

Kevin Cook headshot

Chart Radar: Buy Software, Sell Banks

If a bigger pullback is unfolding in this over-valued market, now is the time to plan your big dip buys.

Vertex (VRTX) Q1 Earnings Beat, Trikafta Drives CF Revenues

Vertex (VRTX) rides high on earnings and revenue beat in Q1.The company raises its revenue guidance on the strong uptake of its newest CF drug, Trikafta. Shares rise in after-hours trading.

CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Misses Revenue Estimates

CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of -5.50% and -97.53%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate CRISPR Therapeutics AG (CRSP) to Report a Decline in Earnings: What to Look Out for

CRISPR Therapeutics AG (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What Makes CRISPR Therapeutics AG (CRSP) a New Buy Stock

CRISPR Therapeutics AG (CRSP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should Know

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $39.54, moving +1.49% from the previous trading session.

CRISPR Therapeutics AG (CRSP) Gains But Lags Market: What You Should Know

CRISPR Therapeutics AG (CRSP) closed at $44.67 in the latest trading session, marking a +0.84% move from the prior day.

Kinjel Shah headshot

What's in Store for Vertex in 2020 After a Remarkable 2019?

In 2020, Vertex's (VRTX) sales are expected to be primarily driven by Trikafta and higher international revenues.

CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know

CRISPR Therapeutics AG (CRSP) closed at $54.33 in the latest trading session, marking a -0.93% move from the prior day.

Benjamin Rains headshot

Expand Your Portfolio with this First Profit Stock Screener

We are in the midst of the fourth quarter earnings season. This makes it a great time to use our 'First Profit' stock screener. The idea is to search for companies that recently reported their first quarterly profit...

CRISPR Therapeutics AG (CRSP) Stock Moves -0.9%: What You Should Know

CRISPR Therapeutics AG (CRSP) closed at $51.95 in the latest trading session, marking a -0.9% move from the prior day.

Vertex (VRTX) Q4 Earnings Beat on Solid CF Product Sales

Vertex (VRTX) rides high on earnings and revenue beat in Q4. The company provides solid outlook for 2020 resulting in the shares to go up in after-hours trading.

Can CF Drugs Drive Growth for Vertex (VRTX) in Q4 Earnings?

On Vertex's (VRTX) fourth-quarter earnings call, investor focus will be on the sales uptake of its CF drugs and the unveiling plans for the newly-approved Trikafta triple combination regimen.

Daniel Laboe headshot

SCANS: The FAANG of The Roaring 20s

A new acronym of equities that could define the next decade of investing.

The Zacks Analyst Blog Highlights: Sea Limited, CRISPR, Alibaba, Nvidia and Splunk

The Zacks Analyst Blog Highlights: Sea Limited, CRISPR, Alibaba, Nvidia and Splunk

Daniel Laboe headshot

SCANS: The FAANG Of The Roaring 20s

I have chosen a new acronym of stocks that I believe could change the world in the roaring 20s

CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should Know

CRISPR Therapeutics AG (CRSP) closed at $59.44 in the latest trading session, marking a +0.2% move from the prior day.

Panel Of Zacks Experts headshot

What the Tech?

Let's REALLY dive deep into the abyss which can be tech. Associate Stock Strategist Dan Laboe, Zacks' resident Tech geek joins us.

Benjamin Rains headshot

Find Strong Stocks Heading into 2020 with this First Profit Screen

Wall Street has started to look ahead to 2020. So today we are going to use our 'First Profit' stock screen to help investors find strong stocks heading into the new year...

Kevin Cook headshot

Trade of the 2020's: Sell Gold, Buy Biotech

In 5 years, you be selling your gold and buying more companies leading the century of biology.

Sweta Killa headshot

Biotech Tops in November: Best ETFs & Stocks

The biotech space of the broad healthcare sector outperformed others in November, courtesy of a series of positive news including study results, regulatory backdrop and deal activities.

The Zacks Analyst Blog Highlights: GLD, CRSP, GBT, ALNY and ARKG

The Zacks Analyst Blog Highlights: GLD, CRSP, GBT, ALNY and ARKG